We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

68 hedge funds and large institutions have $92.1M invested in ImmunityBio in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 8

33% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 15

19.55% more ownership

Funds ownership: 0% → 19.55% (+20%)

8% more funds holding

Funds holding: 63 → 68 (+5)

1% more call options, than puts

Call options by funds: $80K | Put options by funds: $79K

41% less capital invested

Capital invested by funds: $155M → $92.1M (-$62.8M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
68
Holders Change
+5
Holders Change %
+7.94%
% of All Funds
1.7%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
14
Increased
20
Reduced
15
Closed
8
Calls
$80K
Puts
$79K
Net Calls
+$1K
Net Calls Change
-$812K

Top Buyers

1
Millennium Management
Millennium Management
New York
+$970K
2
BFA
BlackRock Fund Advisors
California
+$946K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$587K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$354K
5
Morgan Stanley
Morgan Stanley
New York
+$327K

Top Sellers

1
CC
Callan Capital
California
-$26.5M
2
Franklin Resources
Franklin Resources
California
-$6.21M
3
Bank of America
Bank of America
North Carolina
-$960K
4
ACA
Avoro Capital Advisors
New York
-$563K
5
VEA
Virtus ETF Advisers
New York
-$295K
Name Holding Trade Value Shares
Change 		Change in
Stake
WCM
1
Wildcat Capital Management
New York
$25.7M – – –
Capital Research Global Investors
2
Capital Research Global Investors
California
$15.2M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$12.4M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$11M +$587K +88,033 +5%
BFA
5
BlackRock Fund Advisors
California
$9.58M +$946K +141,805 +9%
Bank of America
6
Bank of America
North Carolina
$2.01M -$960K -143,825 -29%
BIT
7
BlackRock Institutional Trust
California
$1.99M +$128K +19,236 +6%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$1.36M +$42.6K +6,391 +3%
AG
9
Artal Group
Luxembourg
$1.29M – – –
State Street
10
State Street
Massachusetts
$1.1M +$273K +40,848 +27%
Northern Trust
11
Northern Trust
Illinois
$1.05M +$7.63K +1,143 +0.6%
Millennium Management
12
Millennium Management
New York
$832K +$970K +145,407 New
JP Morgan Chase
13
JP Morgan Chase
New York
$813K -$1.27K -190 -0.1%
VIA
14
Vident Investment Advisory
Georgia
$661K +$91.6K +13,732 +13%
Franklin Resources
15
Franklin Resources
California
$631K -$6.21M -931,438 -89%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$553K +$74.4K +11,146 +13%
Charles Schwab
17
Charles Schwab
California
$438K +$32.9K +4,928 +7%
Morgan Stanley
18
Morgan Stanley
New York
$392K +$327K +48,958 +251%
Goldman Sachs
19
Goldman Sachs
New York
$382K +$239K +35,811 +116%
BIM
20
BlackRock Investment Management
Delaware
$364K – – –
ProShare Advisors
21
ProShare Advisors
Maryland
$327K +$23.7K +3,555 +7%
TCIM
22
TIAA CREF Investment Management
New York
$304K +$30.9K +4,630 +10%
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$304K +$354K +53,099 New
Swiss National Bank
24
Swiss National Bank
Switzerland
$243K – – –
TA
25
Teachers Advisors
New York
$232K +$94.3K +14,131 +54%
1
2 3

IBRX Hedge Fund Activity: Q4 2016 in Review

68 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q4 2016, worth a combined $92.1M — down 41% from $155M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new IBRX positions and 8 closed out — a net gain of 6 holders — while 20 added to existing stakes and 15 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $970K. The largest seller was Callan Capital, exiting entirely with an estimated $26.5M sold.

  • 68 institutional investors held ImmunityBio (IBRX) as of Q4 2016, up from 63 in Q3 2016.
  • Funds reported $92.1M of ImmunityBio stock for Q4 2016, down 41% quarter-over-quarter.
  • 14 funds opened new ImmunityBio positions in Q4 2016 and 8 closed out, a net change of +6 holders.
  • The largest ImmunityBio buyer in Q4 2016 was Millennium Management, an estimated $970K added.
  • The largest ImmunityBio seller in Q4 2016 was Callan Capital, an estimated $26.5M sold.

Based on aggregated 13F filings for Q4 2016.